首页> 中文期刊> 《新乡医学院学报》 >IZL-2003免疫治疗系统对改善恶性肿瘤患者放射治疗化学治疗后生活质量及骨髓抑制的影响

IZL-2003免疫治疗系统对改善恶性肿瘤患者放射治疗化学治疗后生活质量及骨髓抑制的影响

         

摘要

目的 观察IZL-2003免疫治疗系统对恶性肿瘤患者放射治疗化学治疗后骨髓抑制和生存质量的影响.方法 将120例放射治疗化学治疗后轻中度骨髓抑制患者随机分为观察组和对照组,每组60例.观察组采用IZL-2003免疫治疗系统每日辐照1次,连续照射10 d为1个疗程;对照组仅常规每日3次给予升白胺2片口服,连服10 d.观察比较2组血常规、临床症状改善及Karnofsky评分(KPS)情况.结果 观察组患者治疗后白细胞计数明显升高,与治疗前比较差异有统计学意义(P<0.05),且明显高于对照组(P<0.05).观察组患者治疗后食欲、疼痛、乏力、睡眠、KPS等方面较对照组均有明显改善(P<0.05).结论 IZL-2003免疫治疗系统可刺激和增强骨髓造血功能,改善患者生存质量.%Objective To observe the effects of IZL-2003 immunotherapy system on marrow suppression and quality of life after treatment by chemoradiotherapy for patients with malignant tumor. Methods One hundred and twenty patients with mild to moderate marrow suppression induced by chemordiotherapy were randomly divided to treatment group and control group,60 cases in each group. The treatment group was given acupoint irradiation with IZL-2003 immune therapy system,once a day, 10 days as one cycle. The control group was only treated with Shengbai'an tablets,2 tablets orally,three times per day for 10 days. Blood routine, improvement of clinical symptoms and Karnofsky ( KPS) scores were compared between the two groups. Results After treatment, leukocyte was higher in treatment group than pretherapy (P <0. 05) ,and also higher than that in control group(P <0. 05) . The improvement of appetite, pain,fatigue, insomnia and KPS score in treatment group was significantly greater than that in control group (P <0. 05). Conclusion IZL-2003 immunotherapy system can stimulate and enhance bone marrow blood-producing function, and improve quality of life in patients with malignant tumor.

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号